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Background: We studied whether thymidylate synthase (TS) genotype has an independent prognostic/predictive
impact on a European population of advanced non-small cell lung cancer (NSCLC) patients receiving pemetrexed.
Methods: Twenty-five patients treated with pemetrexed-based regimens were included. Genomic DNA was isolated
prior to treatment. The variable number of tandem repeat (VNTR) polymorphisms, the G > C single nucleotide
polymorphisms (SNP) and the TS 6-bp insertion/deletion (6/6) in the 3′ untranslated region (UTR) polymorphisms
were analyzed and correlated with overall response rate (ORR), progression-free survival (PFS), overall-survival (OS)
and toxicity.
Results: The genotype +6/+6 predicted a higher ORR among active/former smokers compared to +6/-6 genotype
(100% vs. 50%; p = 0.085). Overall, the 3R/3R genotype predicted a higher ORR (100%) over the rest VNTR
polymorphisms (p = 0.055). The presence of 3R/3R genotype significantly correlated with a superior ORR in patients
without EGFR activating mutations (100%) compared to 2R/2R, 2R/3R and 3R/4R genotype (77.8%, 33.3% and 0%
respectively; p = 0.017). After a median follow-up of 21 months, a trend towards a better PFS, although not
significant, was found among subjects showing 3R/3R polymorphisms (p = 0.089). A significantly superior OS was
found in patients showing 3R/3R genotype rather than other VNTR polymorphisms (p = 0.019). No significant
correlation with the toxicity was observed.
Conclusion: In our series, 3R/3R polymorphism correlated with a superior OS. Also, this polymorphism, when
associated to wild type EGFR, was related to a higher ORR to pemetrexed. Toxicity was not significantly correlated
with a specific TS genotype.
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Lung cancer represents the most frequent cause of can-
cer deaths. More than 225,000 new cases were diagnosed
during 2012 only in the United States of America, ac-
counting for approximately 160,000 annual deaths [1,2].
More than 50% of the patients diagnosed with non-small
cell lung cancer (NSCLC) present advanced disease
(stage III and IV) at onset. The most common histology
is adenocarcinoma representing approximately 80% of
all cases [3].
Pemetrexed, is a multitargeted antifolate drug and one of
the latest active drugs against NSCLC [4] approved for the
first-line [5] (in combination with cisplatin) [6] and second-
line treatment (monotherapy) of patients with non-
squamous histology [7]. More recently, pemetrexed gained
approval for its use as a single-agent maintenance therapy
[8] after response/stabilization to four cycles of a platinum
doublet with or without pemetrexed.
Thymidylate synthase (TS) is the main biological target
of antifolate drugs such as pemetrexed or 5-fluorouracil.
Different studies have evaluated the correlation between
tumor TS expression and TS genotype and the prognosis
of patients with different cancer types treated with anti-
folates [9-11]. In NSCLC, constitutive expression of TS
is lower in tumors with adenocarcinoma histology than
among those with squamous differentiation [12]. This
finding could possibly explain the higher efficacy of the
drug among non-squamous histology patients. The po-
tential predictive role of TS polymorphisms in NSCLC
has never been studied in a European population. In
addition, how differential TS genotypes may impact on
the outcome of patients depending on their smoking sta-
tus or with Epidermal Growth Factor Receptor (EGFR)
activating mutations tumors is to be determined.
Finally, although the toxicity profile described in most pa-
tients receiving pemetrexed in combination or as a single
agent is usually favorable, there are several reported cases
of fundamentally dermatological, hematological and poten-
tially serious renal toxicities, even when the recommended
vitamin prophylaxis guidelines have been followed [13-15].
Nonetheless, the tumor TS levels or its polymorphisms in
each patient could explain these cases of severe toxicity, as
it has been suggested in other neoplasms treated with other
antifolate drugs [9]. The potential association between dif-
ferent TS genotypes and the toxicity experienced by a
European population of patients with NSCLC receiving
pemetrexed is also to be studied.
Three different types of polymorphisms have been de-
scribed in the TS gene. In the gene promoter, there is a
variable number of tandem repeats (VNTR) of 28 pb in
the 5′- region. Thus, cases of two or three repetitions of
this tandem TS gene promoter enhancer region (TSER)
have been described [16]. A second type of polymorph-
ism consists in a change in a single nucleotide (G > C),in one of the sequences of the repetition comprising a
single nucleotide polymorphism (SNP) [16]. A third mo-
dality of polymorphisms consists in the deletion or in-
sertion of 6 pair of bases (bp) in the 3′-UTR region
(untranslated region) [16].
In summary, the potential usefulness of TS genotype
as an independent prognostic factor or predictor of re-
sponse to pemetrexed-based regimens in a European
NSCLC population has not been studied. Similarly, no
clear evidence is available about the potential correlation
between the different TS genotypes and the toxicity ex-
perienced by those patients.
Therefore we decided to investigate the three known
polymorphisms of TS gene, and their correlation with
objective response rate (ORR), progression-free survival
(PFS) and overall survival (OS), as well as toxicity in
European patients with advanced NSCLC treated with
pemetrexed-based regimens.
Methods
Patients and samples
Overall, 25 consecutive stage III-IV NSCLC patients
treated at a single institution, from which peripheral
blood samples were available, were analyzed. All of them
received pemetrexed-based regimens in the first, second
or third line settings, according to our institutional
therapeutic protocols.
After the informed consent was obtained from all
patients, 10 ml of peripheral blood samples were col-
lected before the administration of the first cycle of a
pemetrexed-containing regimen. Blood samples were
stored at the Biobank of the University of Navarra and
were processed following standard operating procedures
approved by the Ethical and Scientific Committees.
Tumor ORR to the treatment was assessed using com-
puterized tomography (CT) scans every two pemetrexed-
based chemotherapy cycles and categorized according
to the Response Evaluation Criteria In Solid Tumors
(RECIST) v1.1, as per institutional protocol.
The toxicities recorded during pemetrexed-based treat-
ment were graded according to the Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.
TS enhancer region genotyping analysis
The genomic DNA was extracted from the peripheral leu-
cocytes. The genotypes of the TSER (VNTR) and SNP were
determined by polymerase chain reaction (PCR). The vari-
able number tandem repeat (VNTR) of 28 bp polymorph-
ism and the G→C SNP in the first and second repeat
were analyzed. A DNA fragment was amplified using previ-
ously described PCR conditions and primers [17], and dir-
ectly sequenced using an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA). The
forward primer 5′-CGTGGCTCCTGCGTTTCC-3′ and
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used. A modification of conventional conditions was neces-
sary. PCR was performed in a reaction mixture with dNTP:
0.35 μl, Buffer: 0.25 μl, MgCl2: 17.5 μl, Tap polymerase:
0.5 μl, H2O: 18 μl, primers 0.1 + 0.1 μl, DMSO: 1.25 μl and
DNA: 2 μl. The cycling conditions were denaturation 95°C
for 10 minutes, and 30 cycles at 95°C for one minute, then
at 64°C for one minute, and 72°C one minute, and finally,
seven minutes at 72 ºC. Aliquots of amplified fragments
were separated on a 3% agarose gel and the TS VNTR
genotype was determined, staining 2R (210 base pairs; bp)
and 3R (238 bp) alleles. After that we performed a PCR-
restriction fragment length polymorphisms (RFLP), by Hae
III digestion. The mixture was PCR product: 10 μl, H2O:
7 μl, Buffer 2 μl, and Hae III: 1 μl. After that we incubated
the mixture at 37°C overnight. Aliquots of digested frag-
ments were separated on 12% acrylamide gel and the SNP
genotype was determined. The digestion of fragments
showed the different genotypes 2RGC: 66, 47, 46, 44 and
7 bp, 2RCC: 113, 46, 44 and 7 bp, 3RGGCC (3RG): 66, 47,
46, 44, 28 and 7 bp, 3RGCC (3RC): 94, 47, 46, 44 and 7 bp.
TS 3′UTR region genotyping analysis
The 3′UTR polymorphisms were analyzed by Restriction
Fragment Length Polymorphism (RFLP). A fragment
containing the 6 bp deletion/insertion was amplified
using the reverse primer 5′-CAGATAAGTGGCAGTA-
CAGA-3′and the forward primer 3′-CAAATCTGAGG-
GAGCTGAGT-5′ in 10 ul of reaction mixture with
dNTP: 4 μl, Buffer: 5 μl, MgCl2: 4 μl, Tap polymerase:
0.5 μl, H2O: 26.5 μl, primers 4 + 4 μl and DNA: 2 μl.
The cycling conditions were denaturation 95°C for
10 minutes, and 35 cycles at 95°C for 30 minutes, then
at 57°C for 30 minutes, and 72°C one minute, and fi-
nally, seven minutes at 72°C. The fragments were ampli-
fied on 2% agarose gel. Afterwards the products were
digested with Dra I and the mixture of PCR product:
20 μl, BSA 10%: 0.5 μl, Buffer: 5 μl, H2O: 23.5 μl and
Dra I: 1 μl. Posteriorly, the product was incubated one
hour at 37°C. The final digested product was separated
in a 3% agarose gel. The different genotypes were dele-
tion 6 bp/insertion 6 bp, insertion 6 bp/insertion 6 bp
and deletion 6 bp/deletion 6 bp. The expected fragment
sizes by genotyping were deletion 6 bp/insertion 6 bp:
148, 142, 88 and 60 bp, insertion 6 bp/insertion 6 bp: 88
and 60 bp, and deletion 6 bp/deletion 6 bp: 142 bp. We
repeated the PCR three times to ensure final results.
EGFR mutations analysis
As per institutional protocol, all patients with advanced
NSCLC were tested for EGFR activating mutations be-
fore treatment initiation. In brief, after having the sam-
ples fixed in alcohol and stained by Papanicolau stain,
DNA was extracted and amplified by PCR technique,using EGFR gene exons 18, 19, 20 and 21 specific
primers. ABI PRISM® 310 Genetic Analyzer equipment
was used for the analysis of the sequencing reactions
with both forward and reverse primers.
Statistical analysis
Fisher’s exact test was used to investigate the correlation
between each genotype and the response to the treat-
ment and the toxicity presented. Kaplan-Meier curves
and log-rank test or Tarone-Ware test, when indicated,
were calculated to correlate each genotype with the sur-
vival outcomes (PFS and OS). For the subgroup analysis,
EGFR mutation status and smoking history were consid-
ered in order to analyze potential differences in clinical
outcome measures (ORR, PFS and OS).
The SPSS 15.0 software (SPSS, Inc., Chicago, IL) was
employed to perform the statistical analysis.
Results
Patients’ characteristics and treatment
The clinical and pathological characteristics of the pa-
tients included are summarized in Table 1. In brief, our
cohort was mainly composed by males with a median
age of 59 years and a past smoking history showing good
performance status. Most of the patients showed adeno-
carcinoma histology (88%) and showed distant metasta-
sis (M1) at onset (72%). Most of the patients received a
pemetrexed-based regimen in first line (84%). After a
median follow up of 21 months, 80% of patients have
already progressed and 52% of them have died due to
disease progression (Table 1).
In addition, in 8 out of the 18 subjects showing mul-
tiple brain metastases at onset, conventional whole-brain
radiotherapy (300 cGy) was administered between first
and second chemotherapy cycles, following our institu-
tional treatment guidelines.
Finally, 4 out of the 7 patients showing no distant me-
tastases at onset responded to the pemetrexed-based in-
duction chemotherapy. As per institutional protocol, all
four subjects underwent a 3-D conformal radiotherapy
program with concurrent chemotherapy, as previously
published [18].
Correlation between ORR to the treatment and
polymorphisms
We studied the potential correlation between the differ-
ent polymorphisms observed and the response to the
treatment obtained (Table 2). For this purpose, any kind
of radiological response (complete or partial response),
was compared to no response to the treatment (disease
stabilization or progression). The presence of 3R/3R
polymorphism seemed to predict a higher ORR (100%),
compared to the rest of the genotypes with a trend to-
ward statistical significance (p = 0.055). In the subgroup
Table 1 Patients’ characteristics
N pts %
Gender
Female 11 44
Male 14 56
Age
<60 13 52
> r =60 12 48
ECOG
0 9 36
1 15 60
2 1 4
Tobacco
Current smoker 4 16
Never smoker 7 28
Former smoker 14 56
Histology
Adenocarcinoma 22 88
Adenocarcinoma poorly differentiated 2 8
Adeno-squamous 1 4
T
T1-2 12 48
T3-4 13 52
N
N0 6 24
N+ 19 76
M
M0 7 28
M1 18 72
Lung metastases
Presence 7 28
Absence 18 72
Liver metastases
Presence 2 8
Absence 23 92
Bone metastases
Presence 10 40
Absence 15 60
Brain metastases
Presence 8 32
Absence 17 68
EGFR
Wild type 23 92
Mutant 1 4
Unknown 1 4
Table 1 Patients’ characteristics (Continued)
Line of treatment
First/Induction (stage III) 2 8
First 21 84
Second 1 4
Third 1 4
Response
Response 18 72
Progression + Stabilization 7 28
Maintenance
No maintenance 18 72
Maintenance 7 28
Progression
Not progressed 6 24
Progressed 19 76
Clinical status
Alive 12 48
Dead 13 52
Eastern Cooperative Oncology Group (ECOG). Epidermal Growth Factor
Receptor (EGFR).
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wild-type EGFR patients showing a 3R/3R genotype
(100%) compared to the 2R/2R (77.8%), 2R/3R (33.3%)
and 3R/4R (0%) was observed (p = 0.017).
No statistically significant differences were observed
comparing the presence and the absence of a SNP G > C
as shown in Table 2.
Overall, a non-significant correlation between the dif-
ferent 3′-UTR polymorphisms and the ORR was ob-
served. However, the genotype +6/+6 seemed to predict
a higher ORR among active/former smokers (A/FS)
compared to +6/-6 (100% vs. 50%; p = 0.085).
Correlation between PFS and polymorphisms
Regarding TSER polymorphisms we found a trend to-
ward statistical significance (p = 0.089) in the differences
in PFS observed among the different genotypes in favor
of the 3R/3R genotype, (Figure 1A).
In the case of the absence or presence of a SNP at the
third repetition (3R allele), we observed a non-significant
increased PFS in the subgroup of patients showing an ab-
sence of SNP (Figure 1B).
Finally, no significant correlations regarding the 3′UTR
genotypes and PFS were observed, (Figure 1C).
Correlation between OS and polymorphisms
In this cohort, we found a significant correlation be-
tween TSER polymorphisms and OS (Figure 2A). The
median OS was not reached for 3R/3R genotype pa-
tients, whereas 2R/3R genotype subjects showed a 70 m
Table 2 Overall response rate to the treatment and
polymorphisms observed
Global distribution of
polymorphisms (Pol)
Response
N (%)
Stabilization or
progression N (%)
p value
VNTR
2R/2R 7 (77.8) 2 (22.2) 0.055
3R/3R 7 (100) 0 (0)
2R/3R 4 (50) 4 (50)
3R/4R 0 (0) 1 (100)
Pol VNTR (Subanalysis by EGFR status; group of native EGFR-patients)
2R/2R 7 (77.8) 2 (22.2) 0.017
3R/3R 7 (100) 0 (0)
2R/3R 2 (33.3) 4 (66.7)
3R/4R 0 (0) 1 (100)
Global distribution of SNP
Absence 6 (85.7) 1 (14.3) 0.626
Presence 12 (66.7) 6 (33.3)
Global distribution of polymorphisms in 3′-UTR
+6/+6 10 (83.3) 2 (16.7) 0.234
+6/-6 6 (54.5) 5 (45.5)
−6/-6 2 (100) 0 (0)
Pol 3′-UTR (Subanalysis by smoking habit stratification; group of
active and former smokers)
+6/+6 8 (100) 0 (0) 0.085
+6/-6 4 (50) 4 (50)
−6/-6 2 (100) 0 (0)
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dian OS of 15 m and 13 m, respectively (p = 0.019),
(Figure 2A).
No significant differences in OS were observed with
regards to the presence/absence of SNP (Figure 2B) or
regarding the 3′-UTR polymorphisms (Figure 2C).
Correlation between toxicity and polymorphisms
The most frequent toxicity was grade (G)1 anemia (28%)
and nausea (20%) and G2 leucopenia (40%). The most
commom G3-4 toxicities were leucopenia (16%), asthe-
nia (8%), anemia (4%), neutropenia (4%) and dyspnea
(4%). Overall, we found no significant correlations be-
tween the toxicity profiles experienced by the patients
and the different TS genotypes (Table 3).
Discussion
Pemetrexed, a multitargeted antifolate drug, is essential
for the first and second-line as well as maintenance
treatment of NSCLC patients with non-squamous hist-
ology [6]. TS is the main biological target of pemetrexed.
Some studies have suggested that TS expression could
be a predictive factor of response in NSCLC [19]. More-
over, some VNTR genotypes have been associated withTS expression and activity in other tumor types such as
colorectal cancer [17].
In NSCLC patients, a correlation between different ge-
notypes and the TS protein expression has been shown
[20]. Shintani et al. [20] also confirmed that the TS
mRNA levels were significantly higher in lung cancer tis-
sues with the 3R/3R genotype as compared to those with
the 2R/2R genotype.
Nonetheless, definitive studies addressing the correlation
of the different genotypes of TS in circulating genomic
DNA with response to the treatment, PFS or OS in
pemetrexed-treated NSCLC European patients are lacking.
The potential influence of the EGFR status on those poly-
morphisms and their correlation with clinical outcome after
pemetrexed-based treatment is also unexplored.
A recent study by Hu et al. [21] investigated the differ-
ent TS polymorphisms in genomic DNA of 90 Asian
NSCLC patients. In contrast with our findings, no spe-
cific genotype regarding the TSER or 3′-UTR polymor-
phisms studied seemed to correlate with a significant
difference in ORR, PFS or OS. This could be explained
by substantial clinical differences between both popula-
tions. Our cohort was constituted by Caucasian patients
compared to the Asian population studied by Hu et al.
In addition, our patients were mostly current or former
smokers (72%) compared to the Asian population that
showed 62% of never smokers. Also in our cohort, the
subjects mainly received pemetrexed-based chemother-
apy as a first line regimen (92%), whereas the cohort
studied by Hu et al. [21] was treated with pemetrexed as
a second or further line in 62.2% of the cases. These re-
markable differences in basic clinical characteristics, and
in particular the ethnicity, between both cohorts are
probably also explaining the differences observed in the
3′-UTR genotype frequency between our population and
the one studied by Hu et al. In our cohort, +6 bp/+6
bp, +6 bp/-6 bp and −6 bp/-6 bp genotypes were found
in 48%, 44% and 8% of the cases, respectively. In con-
trast, 7.8%, 47.8% and 44.4% were respectively found in
the population studied by Hu et al. [21]. In a previous
analysis performed on another Caucasian NSCLC popu-
lation evaluated at the M.D. Anderson Cancer Center
[22], a similar proportion of 3′-UTR genotypes accord-
ing to our findings was observed (49.2% of +6 bp/+6 bp,
42.4% of +6 bp/-6 bp and 8.4% of −6 bp/-6 bp). Add-
itionally, the low prevalence of the +6 bp/+6 bp geno-
type in an Asian population compared to our cohort
may be confirmed by a recent study in which from 106
Asian NSCLC patients investigated, none of them
showed a +6 bp/+6 bp genotype in genomic circulating
DNA [23]. Nontheless, in this latter study [23] a signifi-
cantly higher ORR was observed among patients show-
ing a −6 bp/-6 bp 3′-UTR genotype compared to the
ORR reported for patients presenting a −6 bp/+6 bp
A B
C
Figure 1 Kaplan-Meier curves for progression-free survival (PFS) in months (mo) associated with the different TS polymorphisms.
A: TSER genotypes. B: Presence or absence of SNP. C: 3´UTR genotypes.
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in our cohort, a higher ORR in patients showing
a −6 bp/-6 bp genotype compared to those presenting
a −6 bp/+6 bp polymorphism was also observed (100%
vs. 54.5%). However, the statistical significance was not
reached probably due to the relatively low number of pa-
tients included in our analysis. Interestingly enough, in
the subgroup analysis of our data, the +6 bp/+6 bp
genotype seemed to predict a higher ORR only among
active/former smokers compared to +6 bp/-6 bp (100%
vs. 50%; p = 0.085). This novel observation, if validated
in future studies, could be relevant for selecting specific
drugs for each patient in a second or third line setting.
With regards to the TSER polymorphisms, the presence
of a 3R/3R polymorphism seemed to predict a higher ORR
with a clear trend toward statistical significance (p = 0.055).
Moreover, that difference was even greater and statistically
significant benefiting the subpopulation of wild-type EGFR
patients. To our knowledge, this is the first time that suchobservation has been made. An interesting preclinical study
by Giovannetti et al. [24] investigated the activity profile of
a combination therapy against NSCLC cell lines with differ-
ent genotypes with erlotinib and pemetrexed. Remarkably,
pemetrexed increased EGFR phosphorylation and reduced
Akt phosphorylation. Additionally, erlotinib significantly re-
duced TS expression and activity. Thus, when erlotinib and
pemetrexed were combined, a strong synergism in all
NSCLC cells, regardless of their genetic signature, was ob-
served. This potential crosstalk between the EGFR signaling
pathway and the TS expression and activity could in part
explain our novel findings showing a significantly higher
ORR to pemetrexed in those wild-type EGFR patients har-
boring a 3R/3R polymorphism. However, none of the previ-
ous studies have described the EGFR status of the patients
analyzed and how that status impacted on the ORR to
pemetrexed for certain TS polymorphisms.
In terms of survival, in the present series after a me-
dian follow-up of 21 months, PFS was superior for those
Figure 2 Kaplan-Meier curves for overall survival (OS) in months (mo) associated with the different TS polymorphisms. A: TSER
genotypes. B: Presence or absence of SNP. C: 3´UTR genotypes.
Table 3 Correlation between grades of toxicity and different genotypes
Global distribution polymorphisms (Pol) No toxicity Grade 1-2 Grade 3-4 p value
VNTR polymorphisms
2R/2R 2 (22.2) 4 (44.2) 3 (33.4) 0.545
3R/3R 2 (25) 5 (75) 0 (0)
2R/3R 2 (25) 4 (50) 2 (25)
3R/4R 1 (100) 0 (0) 0 (0)
SNP polymorphisms
Absence 3 (42.9) 4 (57.1) 0 (0) 0.3
Presence 4 (22.2) 9 (50) 5 (27.8)
3′-UTR polymorphisms
+6/+6 3 (25) 6 (50) 3 (25) > 0.05
+6/-6 3 (27.3) 6 (54.5) 2 (18.2)
−6/-6 1 (50) 1 (50) 0 (0)
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statistical significance, as expected considering the higher
ORR observed for patients with the same TSER genotype.
The relatively low statistical power of our clinical cohort
may be accounting for the lack of a full statistical signifi-
cance observed.
Regarding OS, the advantage in PFS observed in pa-
tients showing the 3R/3R genotype translated into a sig-
nificantly higher median OS in patients with the same
polymorphism compared to the rest. Conversely, in the
study by Hu et al. [21] no specific genotype was signifi-
cantly correlated with a superior PFS or OS. As afore-
mentioned, the dramatic differences in the population’s
characteristics between both series might possibly ex-
plain this discordance. In our study, conversely to the
observations made by Wang et al. [23] a significantly su-
perior PFS and OS in patients with the −6 bp/-6 bp 3′-
UTR genotype has not been confirmed. Most probably,
this is also due to the differences in the genotype distri-
bution among populations with markedly different eth-
nicity and epidemiological characteristics.
Finally, in accordance with Wang et al. [23], the tox-
icity profile was not significantly correlated with any TS
genotype in our series.
As aforementioned, this study has some limitations
due to its retrospective nature and the low number of
patients investigated. Both could be responsible for a
low statistical power that may impair our ability to find
significant differences between subgroups of patients.Conclusions
For the first time in a European population of NSCLC pa-
tients receiving pemetrexed, the presence of the TSER 3R/
3R polymorphism significantly correlated with a superior
OS. Moreover, this same polymorphism, when associated
to wild-type EGFR, was correlated with a higher ORR to
pemetrexed. The presence of the +6/-6 bp 3′-UTR geno-
type among active or former smokers was correlated to a
higher ORR showing a trend toward statistical significance.
Finally, pemetrexed-induced toxicity was not significantly
correlated with a specific TS genotype.
These novel data warrant further investigation in lar-
ger prospective series and may help to patient’s selection
if finally validated.Abbreviations
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